ObjectiveTo investigate the clinical effects and safety of tripterygium polyglycoside in the treatment of proteinuria in kidney transplantation patients taking sirolimus.

MethodsAmong 214 kidney transplantation patients treated with sirolimus, the proteinuria(>1.5 g/24 h) in 68 cases was found, and the patients were randomly divided into the control group and observation group(34 cases in each group).The control group was intravenously injected with 1 000 mg of cyclophosphamide combined with 250 mL of 0.9% sodium chloride solution, once a month, and the observation group was treated with 40 to 60 mg/d of tripterygium polyglycoside.Two groups were treated for 6 months.The levels of α₁-microglobulin(α₁-MG), β₂-microglobulin(β₂-MG), urinary albumin(MAU) and 24 h protein in urine in two groups were detected, and the clinical therapeutic effect and adverse reaction were compared between two groups.

ResultsAfter treatment, the urine indicators in two groups significantly decreased(P < 0.01), and the levels of α₁-MG, β₂-MG and 24 h urinary protein in observation group were significantly lower than those in control group(P < 0.05).The differences of the serum levels of Scr, BUN, TG and ALT in two groups between before and after 6 months of tretament were not statistically significant(P>0.05).After 6 months of treatment, the differences of the serum levels of Scr, BUN, TG and ALT between two groups were not statistically significant(P>0.05).The difference of the incidence rate of adverse reaction between two groups was not statistically significant(P>0.05).

ConclusionsTripterygium polyglycoside in the treatment of proteinuria in kidney transplantation patients taking sirolimus has good effect, and can improve the prognosis of pateints.